[
  {
    "ts": null,
    "headline": "Assessing Bio-Techne Shares After a 20% Surge and New Therapeutics Collaboration in 2025",
    "summary": "If you’re weighing your next move with Bio-Techne stock, you’re certainly not alone. After a bumpy stretch over the past year, the stock is making its way back on investors’ watchlists, and for good reason. In just the last month, Bio-Techne shares have climbed an impressive 20.1%, which suggests that something is shifting in how the market views this mid-cap life sciences company. Although the year-to-date return remains in negative territory at -13.5%, that recent surge hints at fresh...",
    "url": "https://finnhub.io/api/news?id=5eb980cdf85658eb47c90a224ed462a674699b8f724cf3c9ff05c17eb19aea56",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760847202,
      "headline": "Assessing Bio-Techne Shares After a 20% Surge and New Therapeutics Collaboration in 2025",
      "id": 137165735,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TECH",
      "source": "Yahoo",
      "summary": "If you’re weighing your next move with Bio-Techne stock, you’re certainly not alone. After a bumpy stretch over the past year, the stock is making its way back on investors’ watchlists, and for good reason. In just the last month, Bio-Techne shares have climbed an impressive 20.1%, which suggests that something is shifting in how the market views this mid-cap life sciences company. Although the year-to-date return remains in negative territory at -13.5%, that recent surge hints at fresh...",
      "url": "https://finnhub.io/api/news?id=5eb980cdf85658eb47c90a224ed462a674699b8f724cf3c9ff05c17eb19aea56"
    }
  }
]